Wednesday, September 19th, 2018


A full text version of this article is available.
To access article obtain online access here or login
Treating Renal Failure with Decorin Gene: An Experimental Study
Authors:  Ning Li, M.S., Huiying Wang, M.B., Wenping Guo, M.B., Mingjun Wang, M.S., Zuan Fan, M.S., Yuan Ning, M.S., Tingting Liu, M.S., Yanxia Zhao, M.S., Guangna Lv, M.S., Xiaotong Wu, M.B., and Xiaolong Xing, M.B.
  Objective: To explore a new approach for treatment of renal insufficiency with decorin (DCN) gene therapy.
Study Design:
Male Sprague Dawley rats were subjected to 5/6 nephrectomy under aseptic conditions and randomly divided into sham-operated group (Group A), operation control group (untreated, Group B), blank control group (treated by empty vector-transfected fibroblast FB [LXSN], Group C), and treatment group (treated by FB [LDCNSN] cells, Group D). Changes in body weight, blood lipids, renal function, and renal tissues were observed. TGF-β1 and DCN expressions in renal tissues were detected with Western blot.
Body weight and blood lipids were similar among the various groups 4 weeks after different treatments. The levels of BUN and Scr in Group D significantly declined as compared with those in Group C (p<0.05). They moderately rose compared with basic values. DCN expression in renal tissues increased significantly in Group D after 4 weeks. There was no significant difference in TGF-β1 expression among Groups D, B, and C. Meanwhile, pathologically, damage to renal interstitium of rats in Group D mitigated significantly. The difference was significant as compared with Groups B and C.
DCN is able to alleviate fibrosis and delay the progression of renal failure.
Keywords:  decorin, fibrosis, gene therapy, gene transfection, renal interstitium, transforming growth factor
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from